646
Participants
Start Date
December 31, 2004
Primary Completion Date
May 31, 2014
Study Completion Date
June 30, 2014
Bortezomib (VELCADE)
1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
Bortezomib (VELCADE)
1.3 mg/m\^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
Doxorubicin hydrochloride (DOXIL/CAELYX)
mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Alabaster
Surprise
Berkeley
Loma Linda
Los Angeles
Sacramento
Norwalk
Stamford
Jacksonville
Miami
Stuart
West Palm Beach
Altanta
Boise
Indianapolis
Lexington
Metairie
New Orleans
Minneapolis
Hackensack
Chapel Hill
Charlotte
Durham
Portland
Philadelphia
Pittsburgh
North Charleston
Nashville
Buenos Aires
Ciudad de Buenos Aires
La Plata
Mendoza
Adelaide
Darlinghurst
Melbourne
Perth
Sydney
Graz
Innsbruck
Salzburg
Vienna
Wels
Brussels
Ghent
Leuven
Mont-Godinne
Vancouver
Hamilton
Ottawa
Montreal
Québec
N/a N/a
Brno
Olomouc
Praha 2 N/A
Angers Cedex 1 N/A
Bobigny
Créteil
Lille Cedex N/A
Nantes
Pierre-Bénite
Toulouse
Tours
Vandœuvre-lès-Nancy
Haifa
Jerusalem
Petah Tikva
Ramat Gan
Rehovot
Tel Aviv
Amersfoort
Amsterdam
Amsterdam-Zuidoost
Delft
Groningen
Nieuwegein
Nijmegen
Rotterdam
The Hague
Utrecht
Bialystok
Gdansk
Lodz
Lublin
Warsaw
Wroclaw
Coimbra
Lisbon
Porto
Arkhangelsk
Izhevsk
Moscow
Nizhny Novgorod
Novosibirsk
Obninsk
Saint Petersburg
Yekaterinburg
Singapore
Bloemfontein
Cape Town
Johannesburg
Parktown
Pretoria Gauteng
Barcelona
Madrid
Salamanca
Bath
London
Janssen Research & Development, LLC
INDUSTRY